A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients

Citations Over TimeTop 10% of 2025 papers

Abstract

Cytokine release syndrome (CRS) is a common, acute adverse event associated with T-cell redirecting therapies such as bispecific antibodies (BsAbs). The nature of CRS events data makes it challenging to capture an unbiased exposure-response relationship with commonly used models. For example, simple logistic regression models cannot handle traditional time-varying exposure, and static exposure metrics chosen at early time points and with lower priming doses may underestimate the incidence of CRS. Therefore, more advanced modeling techniques are needed to adequately describe the time course of BsAb-induced CRS. Herein, we present a two-part mixture model that describes the population incidence and time course of CRS following various dose-priming regimens of elranatamab, a humanized BsAb that targets the B-cell maturation antigen on myeloma cells and CD3 on T cells, where the conditional time-evolution of CRS was described with a two-state (i.e., CRS-yes or no) Markov model. In the first part, increasing elranatamab exposure (maximum elranatamab concentration at first CRS event time (C_max,event)) was associated with an increased CRS incidence probability. Similarly, in the second part, increased early elranatamab exposure (C_max,D1) increased the predicted probability of CRS over time, whereas premedication including corticosteroids and IL-6 pathway inhibitors use demonstrated the opposite effect. This is the first reported application of a Markov model to describe the probability of CRS following BsAb therapy, and it successfully explained differences between different dose-priming regimens via clinically relevant covariates. This approach may be useful for the future clinical development of BsAbs.

Related Papers

• → Cross‐priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon(2003)83 cited
• → Presenting signs and symptoms in multiple myeloma: High percentages of stage III among patients without apparent myeloma-associated symptoms(1995)17 cited
• [Autologous transplantation of peripheral hematopoietic cells in a patient with multiple myeloma and renal insufficiency].(1997)
• → PRIMING POTENCY OF THE PRODUCTS OF INDIVIDUAL REGIONS OF THE H‐2 COMPLEX AND THEIR ROLE IN THE RESTIMULATION IN SECONDARY MLC(1978)2 cited
• → Expression of MicroRNA-221 in Korean Patients with Multiple Myeloma(2018)